GlassScriptPhysician profile
Navid Khamooshi
NPI 1841813565
$2,680.12
in general payments reported to CMS, 2019-2025
30 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.73 · 2023: $523 · 2024: $877 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.40 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $363.67 | 2023-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $240.00 | 2023-2025 | Rexulti |
| Pfizer INC. | $210.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $181.64 | 2023-2024 | Airsupra, Breztri |
| Dexcom, INC. | $123.34 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $111.39 | 2024-2025 | Nexletol |
| Lilly USA, LLC | $107.03 | 2023-2025 | Mounjaro, Zepbound, Amyvid |
| Exact Sciences Corporation | $97.75 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $95.33 | 2023-2025 | Rexulti |
| Abbvie INC. | $89.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.97 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.22 | 2022-2024 | Lifevest |
| Alk-Abello, INC | $50.30 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.12 | 2025 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $39.49 | 2024-2025 | |
| Ardelyx, INC. | $37.31 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $34.79 | 2023-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $34.74 | 2023-2024 | |
| Corcept Therapeutics | $34.60 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $34.30 | 2023-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $31.16 | 2023 | Ingrezza, Ongentys |
| Edwards Lifesciences Corporation | $28.74 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Azurity Pharmaceuticals, INC. | $26.66 | 2025 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $26.28 | 2023 | Livalo, Seglentis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.00 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $24.47 | 2023 | |
| Astellas Pharma US INC | $23.10 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $21.09 | 2024 | Verquvo |
| Glaxosmithkline, LLC. | $13.46 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Khamooshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.